Navigation Links
Drug reduces fat by blocking blood vessels
Date:4/23/2013

BOSTONResearchers have long known that cancerous tumors grow collections of abnormal blood cells, the fuel that feeds this disease and keeps it growing. Now, new evidence in an animal model suggests that blood vessels in the fat tissue of obese individuals could provide the same purposeand could provide the key to a new way for people to lose weight. When researchers Jian-Wei Gu, Kristina L. Makey, Edmund Chinchar, Carissa Howie, and Lucio Miele, all from the University of Mississippi Medical Center, gave obese mice a cancer drug that works by inhibiting the growth of blood vessels, these mice lost about 70 percent of their fat mass.

The team will discuss an abstract of their study entitled, "Angiogenesis Inhibitor, Sunitinib, Significantly Reduces Adipose Tissue Mass in High Fat Diet-Induced Postmenopausal Obese Mice," at the Experimental Biology 2013 meeting, being held April 20-24, 2013 at the Boston Convention and Exhibition Center, Boston, Mass. The poster presentation is sponsored by the American Physiological Society (APS), a co-sponsor of the event. As the findings are being presented at a scientific conference, they should be considered preliminary, as they have not undergone the peer review process that is conducted prior to the data being published in a scientific journal.

Treating Fat and Cancer the Same

Dr. Gu, who led the research team, notes that there are only three drugs currently approved in the United States to treat obesity. Unfortunately, he says, these few drugs are only minimally effective and come with a host of undesirable side effects.

"Right now," he says, "we don't have good drugs that lead to very significant weight loss, and none that don't cause other problems."

More than a decade ago, Judah Folkman of Harvard Medical School, whose primary research focus was the growth of blood vessels in cancerous tumors, discovered that fat tissue in mice can be regulated by angiogenesis inhibitorsdrugs that restrain the growth of blood vessels. However, Gu explains, Folkman never pursued this line of research further before his death in 2008.

Building upon Folkman's single paper published on this topic in 2002, Gu, who studies the role of fat tissue in cancer, decided to test whether a drug already developed to inhibit blood vessels for cancer treatment might also reduce fat.

He and his colleagues administered the drug, known as Sunitinib and approved to treat kidney and gastrointestinal tumors, to a mouse model of postmenopausal obesity. These animals, which had their ovaries removed at a young age to put them in premature menopause and fed four weeks of a high fat diet to promote obesity, received Sunitinib daily for two weeks either orally or through abdominal injections. These animals were compared to those of the same model who didn't receive the drug.

Shrinking Blood Vessels, and Fat

After this treatment, researchers found that the mice who received Sunitinib lost significant amounts of weight, with an average loss of 70 percent fat mass. However, notes Gu, their lean mass remained unaffected. Both mice who received the drug orally and those who received abdominal injections lost similar amounts of fat.

In addition to fat loss, Sunitinib also seemed to curb the animals' appetites, with those receiving the drug eating less food once treatment was completepossibly a side effect of losing the fat and the hormones it sends to the brain to stimulate food intake, Gu explains.

Gu emphasizes that more research is necessary before this drug can be tested for human weight loss. Because many angiogenesis proteins exist for various purposes throughout the body, Sunitinib may cause off-target effects that weren't immediately evident in the mouse models, he notes. Additionally, he and his colleagues plan to test whether this drug is also effective with other types of animal models for obesity.

However, according to the researcher, the findings suggest that Sunitinib holds promise for reducing fat mass. "This could be a very good strategy for treating obesity, at least in the short-term," he says.


'/>"/>

Contact: Donna Krupa
dkrupa@the-aps.org
American Physiological Society
Source:Eurekalert

Related biology news :

1. Soy-based S-equol supplement reduces metabolic syndrome risk factors
2. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
3. Laparoscopy reduces the risk of small-bowel obstruction
4. Hot sauce ingredient reduces beer belly fat as a weight-loss surgery alternative
5. The absence of elephants and rhinoceroses reduces biodiversity in tropical forests
6. Drugs from lizard saliva reduces the cravings for food
7. New study: Snacking on raisins significantly reduces overall post-meal blood sugar levels
8. Cystic fibrosis makes airways more acidic, reduces bacterial killing
9. Study in mice discovers injection of heat-generating cells reduces belly fat
10. Eating well during pregnancy reduces babys obesity risk regardless of moms size
11. RTS,S malaria candidate vaccine reduces malaria by approximately one-third in African infants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... Cercacor today introduced Ember TM Sport ... non-invasively measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion ... in approximately 30 seconds. Smaller than a smartphone, using ... to key data about their bodies to help monitor ... Hemoglobin carries oxygen to muscles. When hemoglobin ...
(Date:11/19/2016)... 18, 2016 Securus Technologies, a leading provider ... safety, investigation, corrections and monitoring, announced today that it ... to have an independent technology judge determine who has ... high tech/sophisticated telephone calling platform, and the best customer ... do most of what we do – which clearly ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... DUBLIN , Dec 5, 2016 ... new report "DNA Sequencing - Technologies, Markets and Companies" ... ... This report briefly reviews basics of human genome variations, development ... sequencers are described as well as companies developing them. Various ...
(Date:12/4/2016)... , Dec. 3, 2016  In five studies ... Hematology (ASH) Annual Meeting and Exposition in ... engineering methods to improve the delivery of life-saving treatments ... new methods are designed to carry therapies directly to ... most, which could provide a substantial advantage over traditional, ...
(Date:12/2/2016)... , Dec. 2, 2016  The Multiple Myeloma ... from the MMRF CoMMpass Study SM —the largest and ... precision medicine in multiple myeloma—will be presented at the ... Meeting & Exposition in San Diego ... to optimize treatment strategies, as well as identify pathways ...
(Date:12/2/2016)... CA (PRWEB) , ... December 01, 2016 , ... ACEA ... from its Phase I/II clinical trials for AC0010 at the World Conference on Lung ... to providing an update on the phase I/II clinical trials for AC0010 in patients ...
Breaking Biology Technology: